AR073781A1 - Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa. - Google Patents

Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa.

Info

Publication number
AR073781A1
AR073781A1 ARP090103851A ARP090103851A AR073781A1 AR 073781 A1 AR073781 A1 AR 073781A1 AR P090103851 A ARP090103851 A AR P090103851A AR P090103851 A ARP090103851 A AR P090103851A AR 073781 A1 AR073781 A1 AR 073781A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
glaucoma
treatment
ocular hypertension
composition
Prior art date
Application number
ARP090103851A
Other languages
English (en)
Inventor
Yasuhiro Harada
Junichi Kawasaki
Ryuji Ueno
Tadashi Hayashi
Original Assignee
Sucampo Ag
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag, R Tech Ueno Ltd filed Critical Sucampo Ag
Publication of AR073781A1 publication Critical patent/AR073781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se provee una composicion farmacéutica que comprende: a) un compuesto de prostaglandina; (b) un alcohol de azucar, (c) un poliol; y (d) un portador aceptable para uso farmacéutico. La composicion de la presente se puede almacenar en forma estable incluso en un envase de polietileno. Además, la composicion de la presente se puede almacenar en forma estable durante un largo tiempo incluso si contiene solo una pequena proporcion de un agente conservante. Reivindicacion 4: La composicion farmacéutica de la reivindicacion 1, caracterizado porque el compuesto de prostaglandina es isopropil unoprostona. Reivindicacion 6: La composicion farmacéutica de la reivindicacion 1, caracterizado porque se utiliza para el tratamiento de glaucoma y/o hipertension ocular o retinitis pigmentosa.
ARP090103851A 2008-10-07 2009-10-07 Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa. AR073781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10340308P 2008-10-07 2008-10-07

Publications (1)

Publication Number Publication Date
AR073781A1 true AR073781A1 (es) 2010-12-01

Family

ID=41479177

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103851A AR073781A1 (es) 2008-10-07 2009-10-07 Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa.

Country Status (11)

Country Link
US (1) US20100087540A1 (es)
EP (1) EP2341894B1 (es)
JP (2) JP5320388B2 (es)
KR (1) KR101166739B1 (es)
CN (1) CN102215817B (es)
AR (1) AR073781A1 (es)
CA (1) CA2739710A1 (es)
ES (1) ES2392221T3 (es)
HK (2) HK1159501A1 (es)
TW (1) TWI403324B (es)
WO (1) WO2010041722A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN102946883A (zh) * 2010-04-12 2013-02-27 株式会社·R-技术上野 治疗视网膜疾病的方法及眼用组合物
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69105349T2 (de) * 1990-05-22 1995-04-06 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung.
US6770675B2 (en) * 1997-03-17 2004-08-03 Novartis Ag Compositions and methods for reducing ocular hypertension
CN1146423C (zh) * 1998-07-14 2004-04-21 阿尔康实验室公司 前列腺素产品
WO2002022106A2 (en) * 2000-09-14 2002-03-21 Novartis Ag Stable ophthalmic preparation
US20040076678A1 (en) * 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution
ES2431640T3 (es) * 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
US20070093507A1 (en) * 2003-09-05 2007-04-26 Lambrou George N Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
EP2420223B1 (en) * 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes

Also Published As

Publication number Publication date
WO2010041722A3 (en) 2011-01-27
EP2341894B1 (en) 2012-08-29
WO2010041722A2 (en) 2010-04-15
ES2392221T3 (es) 2012-12-05
JP2011509237A (ja) 2011-03-24
CN102215817B (zh) 2013-06-12
CN102215817A (zh) 2011-10-12
CA2739710A1 (en) 2010-04-15
TW201016219A (en) 2010-05-01
JP5320388B2 (ja) 2013-10-23
KR20100065126A (ko) 2010-06-15
KR101166739B1 (ko) 2012-07-23
TWI403324B (zh) 2013-08-01
US20100087540A1 (en) 2010-04-08
JP2013177446A (ja) 2013-09-09
HK1159501A1 (en) 2012-08-03
EP2341894A2 (en) 2011-07-13
HK1162935A1 (en) 2012-09-07

Similar Documents

Publication Publication Date Title
ES2528216T3 (es) Agente de lavado o de limpieza protector del color
PE20100156A1 (es) Tratamiento de nafld
AR072123A1 (es) Composiciones que contienen un agente activo solvatado adecuadas para ser dispensadas como un aerosol de gas comprimido
AR048618A1 (es) Confitura congelada y dispositivo para sostener
AR050946A1 (es) Composiciones para el tratamiento de la ropa.
AR029836A1 (es) Articulo para dispensar un activo volatil
ECSP10010598A (es) Metodos y composiciones líquidas de limpieza
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
AR069969A1 (es) Formulacion liquida que contiene anticuerpo en alta concentracion
AR063571A1 (es) Aparato para el agregado de agentes o ingredientes solubles a un líquido portador, para su administración oral a través de un sorbete
PE20120169A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
AR069665A1 (es) Composiciones para modelar el cabello y metodos de uso
ECSP10010167A (es) Composiciones oftálmicas novedosas
AR109357A2 (es) Composición farmacéutica parenteral con tolerancia en el sitio de inyección
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
CO7111278A2 (es) Formulación antiadherente que incluye un compuesto de amonio cuaternario y un alcohol graso
AR084708A1 (es) Formulaciones de enjuague bucal para ser usadas con un dispositivo de suministro en el cepillo de dientes
WO2011139615A3 (en) Method for making a personal care product
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
AR043662A1 (es) Derivados de guanidina
AR045094A1 (es) Formulaciones liofilizadas de cci-779
AR073781A1 (es) Composicion farmaceutica para el tratamiento del glaucoma, hipertension ocular o retinitis pigmentosa.
MY151372A (en) Packing body

Legal Events

Date Code Title Description
FB Suspension of granting procedure